|DEF 14A||definitive proxy statement||Apr 30, 1997||126.5 KB|
|10-K||annual report||Mar 19, 1997||285.7 KB|
|SC 13G/A||amended statement of beneficial ownership||Feb 20, 1997||32.3 KB|
|SC 13G/A||amended statement of beneficial ownership||Feb 14, 1997||54.1 KB|
|SC 13D||general statement of beneficial ownership||Dec 30, 1996||50.4 KB|
|10-Q||quarterly report||Nov 14, 1996||76.9 KB|
|8-K||current report||Oct 9, 1996||273.6 KB|
|SC 13D/A||amended general statement of beneficial ownership||Sep 19, 1996||273.8 KB|
|8-K||current report||Aug 23, 1996||59.1 KB|
|8-A12G||registration statement||Aug 23, 1996||367.9 KB|
|10-Q||quarterly report||Aug 13, 1996||182.6 KB|
|8-K||current report||Jun 18, 1996||281.8 KB|
|SC 13D||general statement of beneficial ownership||May 24, 1996||467.0 KB|
- Corporate Governance
- Management & Board
- Stock Information
- SEC Filings
- Quarterly Results
- Analyst Coverage
- Webcasts & Presentations
- Scientific Publications & Presentations
- Frequently Asked Questions
© 2004-2017 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.